Related Experiment Videos
Cholelithiasis in pediatric organ transplantation: detection and management
1Department of Pediatrics, Pediatric Gastroenterology and Hepatology, University of Hamburg, Germany. ganschow@uke.uni-hamburg.de
Insights
Gallstones (cholelithiasis) are common in pediatric transplant patients, particularly heart recipients. Ursodeoxycholic acid shows promise for treatment, but further research is needed.
Area of Science:
- Pediatric Gastroenterology
- Transplantation Medicine
- Hepatology
Background:
- Cholelithiasis incidence and causes in pediatric solid organ recipients are not well-defined.
- Established risk factors, alongside drug therapy, sepsis, parenteral nutrition, and surgical complications, contribute to gallstone formation in these vulnerable patients.
- Data on pediatric transplant patients are limited and varied, with heart recipients showing a higher incidence.
Purpose of the Study:
- To review current data on the incidence, detection, and management of cholelithiasis in pediatric organ transplant recipients.
- To highlight the unique risk factors and challenges in this population.
- To evaluate potential therapeutic strategies.
Main Methods:
- Review of existing literature on cholelithiasis in pediatric solid organ transplantation.
- Analysis of incidence, risk factors, and treatment outcomes.
- Discussion of pharmacological and surgical management options.
Main Results:
- The incidence of cholelithiasis varies among pediatric transplant recipients, appearing substantially higher in heart recipients compared to kidney or liver recipients.
- Surgical intervention remains the primary treatment for symptomatic gallstones.
- Ursodeoxycholic acid demonstrates promising pharmacological properties and initial clinical impact for gallstone management.
Conclusions:
- Further studies are required to determine the efficacy of prophylactic ursodeoxycholic acid therapy.
- Management strategies for cholelithiasis in pediatric transplant recipients need tailored approaches based on graft type and patient condition.
- Continued research is essential to fully understand and address gallstone formation in this population.
Abstract:
The real incidence and the underlying causes of cholelithiasis in pediatric solid organ recipients is probably not exactly known. In addition to well-established risk factors for cholelithiasis, children after heart, kidney, or liver transplantation may develop gallstones due to drug therapy, sepsis, parenteral nutrition, or surgical complications. For pediatric patients, data are very limited and heterogeneous. However, the incidence in pediatric heart recipients seems to be substantially higher compared with kidney or liver graft recipients. In this review article the present data are discussed focusing on incidence, detection, and management of cholelithiasis in pediatric organ transplantation. In general, surgery is the therapy of choice in symptomatic patients; however, the pharmacological profile of ursodeoxycholic acid and the first results on its clinical impact are promising. The value of prophylactic therapy with ursodeoxycholic acid must be determined in further studies.